PharmiWeb.com - Global Pharma News & Resources
31-Jan-2019

Q4 Incl. Full Year Report 2018

UPPSALA, Sweden, Jan. 30, 2019 /PRNewswire/ --

Q4 2018 highlights

Total net revenues of SEK 227.1 million (191.0), up 18.9 percent from Q4 previous year

Zubsolv® US net revenue of SEK 166.7 million (126.5), up 31.8 percent in SEK and 21.3 percent in local currency compared to the same period last year

EBITDA of SEK 42.8 million (35.3), EBITDA excluding IP litigation costs of SEK 69.2 million (43.1)

US EBIT of SEK 62.0 million (19.8)

Cash flow from operating activities of SEK 71.7 million (-23.0), building a cash balance of SEK 589.8 million (327.9)

Earnings per share, before dilution SEK 1.49 (0.77), earnings per share after dilution SEK 1.47 (0.77)

The US field force, previously contracted, was internalized to further strengthen the commercial organization

US Court of Appeals denied Actavis's petition for rehearing regarding validity of the Zubsolv patent ´330

All rights to Zubsolv in all countries outside the US were regained from Mundipharma

Important events after the period

Positive results from human PK study assessing Orexo's new intranasal naloxone formulations (OX124) for opioid overdose reversal

The US District Court of Delaware issued a final, non-appealable judgement that Actavis's generic Zubsolv products infringe the US patent ´330, preventing Actavis from launching their infringing generics in the US until 2032

The Board of Directors proposes that no dividend is paid for the financial year 2018

Editor Details

Related Links

Last Updated: 31-Jan-2019